Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | DPP4 | P27487 | 11/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198493 | 0.86 | NPY4R (0.42) | OPRK1DPP4DPP7DPP8DPP9 | |
| SCHEMBL1649751 | 0.83 | DPP4 (0.56) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL29615168 | 0.81 | GNRHR (0.45) | NTSR2NTSR1 | |
| SCHEMBL29391291 | 0.81 | GNRHR (0.47) | OPRK1NTSR2NTSR1 | |
| SCHEMBL29383471 | 0.81 | GNRHR (0.45) | NTSR2NTSR1 | |
| SCHEMBL2182440 | 0.79 | DPP4 (0.52) | OPRK1DPP4DPP7DPP8DPP9 | |
| SCHEMBL9450511 | 0.79 | DPP4 (0.45) | OPRK1DPP4DPP7DPP8DPP9 | |
| SCHEMBL2182382 | 0.79 | DPP7 (0.52) | DPP4DPP7DPP8DPP9ITGB3 | |
| SCHEMBL29058389 | 0.79 | DPP4 (0.48) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL2194031 | 0.78 | NPY4R (0.48) | OPRK1DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105769774-A | Degarelix acetate freeze-dried composition for injection and preparation method thereof | 张光泉 | 2016-07-20 | — | — | CN | disclosed |
| CN-105749245-A | Anti-cancer drug degarelix acetate injection and preparation method thereof | 张光泉 | 2016-07-13 | — | — | CN | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| CN-102204889-B | Degarelix acetate lyophilized powder injection and preparation method thereof | BENGBU BBCA TUSHAN PHARM CO | 2013-09-18 | — | — | CN | disclosed |
| CN-102204889-A | Degarelix acetate lyophilized powder injection and preparation method thereof | BENGBU BBCA TUSHAN PHARM CO | 2011-10-05 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRK1 3229/4885DPP4 193/4885DPP7 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.